



SciGen Announces The Termination of its Collaborative Research with Intercell

12TH November 2006: SciGen Limited (ASX: SIE) SciGen and Intercell have terminated their collaborative agreement for the development of a therapeutic hepatitis B vaccine using SciGen antigen derived from mammalian cell (CHO), Sci B Vac™, a third generation vaccine which covers the three epitopes of the Hepatitis B virus, in combination with Intercell adjuvant IC31®.

The preliminary results in the pre-clinical stage with Sci B Vac™ formulated with Intercell adjuvant IC31® have shown only a limited augmentation of immunogenicity as compared to Sci B Vac™ when formulated in alum. Preclinical studies to develop a feasible formulation that included IC31® led to the conclusion that substantial further efforts and investment would have been required to establish a viable clinical product candidate.

It is a further indication that Sci B Vac™ is highly immunogenic and difficult to outperform.

SciGen will continue its quest for the development of a therapeutic hepatitis B vaccine with Sci B Vac™.

About SciGen™:

SciGen Ltd is a biopharmaceutical company involved in commercializing later stage research. It co-develops and markets biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.

SciGen acquires rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and Biosimilar products, which allow for faster entry into the market, as Biosimilar products have undergone much of the clinical development and trials required to bring drugs to market. This minimizes the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's competitive advantage is in identifying research with commercial potential at an early stage to which it adds its expertise in clinical development, gaining regulatory approval and bringing products to market.

SciGen is a Singaporean biotechnology company, established in 1988 and listed on the Australian Stock Exchange (ASX code SIE). SciGen is headquartered in Singapore, with subsidiary companies in the USA, Australia, S. Korea, Hong Kong, Philippines, Vietnam, Israel and India, a Joint Venture in China, commercial partners in Europe and collaborative partners in the USA and the Netherlands.

Further information:

Company – Investor Relations	Company
Ms. Maria Arroyan SciGen Australia +61 2 9234 1700 email: mariaaroyan@scigen.com.au	Saul Mashaal Chairman, Founder & CEO SciGen Ltd. + 61 2 9234 1700 +65 9630 5691 (Mobile)